Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690
NCT ID: NCT00937781
Last Updated: 2017-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
307 participants
OBSERVATIONAL
2011-02-08
2011-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma
NCT00897546
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
NCT00897520
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
NCT01886235
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
NCT00091689
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim
NCT01489423
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To validate the prognostic role of several biomarkers suggested by gene expression profiling and tissue microarray (TMA) studies (e.g., NCOA3, SPP1, and RGS1) on the outcome associated with melanoma in the EST-1690 cohort using IHC analysis.
* To examine the potential predictive role of such biomarkers in patients undergoing adjuvant interferon alfa therapy.
* To analyze the correlation between the intensity of biomarker expression and survival of this cohort both in the observation and in the interferon-treated groups.
* To examine the prognostic role of these biomarkers on the outcome associated with melanoma in the EST-1690 cohort using quantitative-PCR.
* To isolate RNA from the primary specimens from patients enrolled in the EST-1690 cohort to assess the expression of genes suggested by cDNA microarray and IHC analyses (e.g., NCOA3, SPP1, and RGS1) as prognostic or predictive markers.
OUTLINE: Samples from the EST-1690 cohort are obtained and analyzed for several biomarkers (i.e., NCOA3, SPP1, and RGS1) via immunohistochemistry and quantitative PCR. RNA is isolated from the specimens to assess gene expression via quantitative PCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
gene expression analysis
microarray analysis
polymerase chain reaction
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of melanoma
* No metastatic disease at diagnosis
* Treated on protocol EST-1690
* Primary tumor tissue specimens available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
ECOG-ACRIN Cancer Research Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed Kashani-Sabet, MD
Role: STUDY_CHAIR
University of California, San Francisco
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECOG-E1690T1
Identifier Type: -
Identifier Source: secondary_id
CDR0000631851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.